186 results about "Glucose control" patented technology

The invention provides an exosome, a mesenchymal stem cell and application of the exosome and the mesenchymal stem cell in treatment of type 2 diabetes mellitus, and belongs to the technical field of biological medicine. The exosome secreted by the umbilical cord mesenchymal stem cells of the composite pretreatment group is used for treating the type 2 diabetes mellitus, and the obvious advantages are shown. Compared with a model control group, the exosome has the advantages that the glucose tolerance of diabetic rats treated by the exosome is obviously improved, the blood glucose value is reduced by about 47.5% within 120 minutes, the area under a blood glucose curve (AUC) is reduced by about 50.5%, the serum insulin is increased by about 147.7%, insulin secretion is effectively promoted, the glycosylated hemoglobin level is obviously reduced, and the long-term blood glucose control effect is good. By integrating various indexes, the exosome obtained by the composite pretreatment scheme provided by the invention has a remarkable effect of improving the illness state of rats with type 2 diabetes mellitus, provides a new effective strategy for treatment of type 2 diabetes mellitus, and shows a good application prospect.

The present invention provides a method for increasing glycemic control in a patient in need thereof, by administering tirzepatide, or a pharmaceutically acceptable salt thereof. The present invention provides a method for improving weight management in a patient in need thereof, by administering tirzepatide, or a pharmaceutically acceptable salt thereof. Further providing a method for treating a condition selected from atherosclerosis, chronic kidney disease, NAFLD, and NASH. Further provided is a method to prevent or induce remission of diabetes comprising administration of tirzepatide, or a pharmaceutically acceptable salt thereof. Further provided is a dosing regimen for increasing glycemic control, improving weight management, and / or treating dyslipidemia.

The invention discloses a real-time adjusting method for insulin infusion volume, which adopts a closed-loop control method, and dynamically adjusts the infusion volume of an insulin pump based on a comparison result of a predicted blood glucose parameter and a preset blood glucose range through collected blood glucose data and predicted future blood glucose data, thereby realizing more accurate blood glucose control. The invention further discloses a closed-loop infusion system designed based on the real-time adjustment method. The closed-loop infusion system comprises a controller, a blood glucose detection system, an insulin pump and a continuous glucose monitoring system. Compared with open-loop control, the closed-loop control can monitor the blood glucose level of the patient in real time and automatically adjust the insulin infusion amount according to real-time data, and the high-automation system can more accurately maintain the blood glucose within the target range and reduce blood glucose fluctuation. Moreover, the closed-loop control system reduces the requirements of patients or medical staff for manually calculating and adjusting the insulin dosage, so that personal errors are reduced, automatic adjustment can better adapt to individual differences and dynamic changes of the patients, the burden of the patients on blood glucose monitoring and insulin dosage adjustment is reduced, and the safety and effectiveness of treatment are improved.

The embodiment of the invention discloses a blood glucose index evaluation method, electronic equipment and a storage medium, and the method comprises the steps: obtaining the corresponding heart rate data of a target user in an evaluation time period, carrying out the feature extraction processing of the heart rate data, obtaining the corresponding target heart rate feature of the target user in the evaluation time period, and obtaining the target heart rate feature of the target user in the evaluation time period; inputting the target heart rate feature and a target calibration parameter corresponding to the target user into a blood glucose evaluation model, and predicting blood glucose control index data corresponding to the target user in the evaluation time period through the blood glucose evaluation model. The target heart rate features and the target calibration parameters are used as input of a blood glucose evaluation model, and the blood glucose management and control index data of the target user in the evaluation time period are predicted through the blood glucose evaluation model, so that it is ensured that the obtained heart rate data corresponding to the target user in the evaluation time period are utilized; and the accuracy of the blood glucose management and control index data corresponding to the target user in the evaluation time period is determined, and meanwhile, the cost of blood glucose monitoring is greatly reduced.

Techniques, systems and devices for glycemic control are presented. An apparatus may include a display device and a processor in electronic communication with the display device. The apparatus includes a memory communicatively connected to the processor. The memory includes instructions configuring the processor to generate a user interface through the display device and receive user input through the user interface. The processor is configured to implement an activity mode of a plurality of activity modes of a wearable medical device based on the user input. The activity mode is indicative of temporary conditions affecting blood glucose levels of the user. The processor is configured to receive biological data from a user through a biological sensor in communication with the processor and calculate an amount of medication to deliver to a user based on the biological data and the implemented activity mode.

The invention discloses a training method of a blood glucose control model and a blood glucose control method and system, and belongs to the technical field of blood glucose control. According to the method, a framework combining a blood glucose control model and a reinforcement learning model is constructed; wherein the blood glucose control model is a full-connection neural network with two layers; the number of neurons in the first layer of the network is 3, and an adopted activation function is a linear function; the number of neurons in the second layer of the network is 1, the adopted activation function is a nonlinear activation function, the output value domain of the nonlinear activation function is bounded, the upper bound is a positive number, and the lower bound is a negative number. The blood glucose control model is a model evolved after a classic PID algorithm is improved based on a blood glucose control task, the parameter space of the model comprises the parameter space of the classic PID algorithm, and the model has a wider range, can extract features with higher expression ability, is more adaptive to a reinforcement learning process, and can simply and efficiently realize accurate control of blood glucose.

The present invention discloses modified-release bilayer tablets consisting of two layers, layer 1 consisting 500 mg sustained release metformin and layer 2 consisting 250 mg normal release metformin and 5mg / 10mg delayed-release dapagliflozin. This formulation is meticulously designed to regulate blood glucose levels effectively over an extended period. Immediate-release metformin swiftly addresses acute glucose spikes, while sustained-release metformin ensures prolonged glucose control, minimizing fluctuations throughout the day. The delayed-release dapagliflozin component allows for controlled and timed release, managing persistent hyperglycemia synergistically with metformin. By optimizing efficacy and minimizing glucose fluctuations, this innovative formulation offers a promising solution for stable glycemic control in individuals with diabetes. Present invention aims to improve patient outcomes and enhance overall quality of life by maintaining stable glucose levels and reducing the risk of complications associated with uncontrolled diabetes.

According to one embodiment of the present disclosure, provided is a method for assisting blood glucose control of a subject using a computer system, the method comprising: acquiring a target set by the subject; acquiring a GA value of the subject; generating a GA value trend using the plurality of GA values; outputting a GA value trend to the object person; and outputting the target set by the subject to the subject.

The present invention provides a method for improving glycemic control in a patient in need thereof, comprising administering to said patient, tirzepatide, or a pharmaceutically acceptable salt thereof, wherein said patient has failed to reach their HbA1c goal using GLP-1 RA treatment. The present invention provides a method for improving weight management in a patient in need thereof, comprising administering to said patient tirzepatide, or a pharmaceutically acceptable salt thereof, wherein said patient has failed to reach their weight management goal using GLP-1 RA treatment.

The invention belongs to the field of insulin infusion devices, and discloses an intelligent insulin infusion device for diabetic patients and a blood glucose control method.The device comprises a blood glucose monitoring module, an intelligent insulin infusion module, an AI control center, a user interaction module and a safety monitoring module. The DNN model can accurately predict the short-term blood glucose trend, and the response speed and accuracy of insulin infusion are remarkably improved; a dynamic adjustment algorithm dynamically adjusts the insulin dosage according to individual differences of patients and real-time data, and the risk of complications is reduced; the calculation and response time is reduced through combination of the model and the algorithm, and millisecond-level insulin infusion control is achieved; the system monitors and corrects an insulin infusion strategy in real time, reduces the risk of hypoglycemia and infusion failure, and ensures the safety of a patient. According to the invention, the living quality and the blood glucose management level of the diabetic patient are obviously improved, and meanwhile, the application and development of the intelligent medical technology in chronic disease management are promoted.

The invention relates to the field of intelligent medical monitoring, in particular to a diabetic multi-source data real-time analysis method based on a large language model, and the method mainly comprises the steps: continuously collecting multi-source data of a patient from a CGM device, an intelligent watch and a mobile terminal, and enabling the multi-source data to at least comprise blood glucose data, heart rate and input data; constructing a deep learning model comprising four layers of attention mechanisms, inputting the fusion data into the deep learning model, predicting a blood glucose trend within a preset time by using a sliding time window to obtain a blood glucose prediction result, and pushing the blood glucose prediction result to the mobile terminal or the smart watch; and performing reinforcement learning on the large language model based on a deep Q network architecture, and when the blood glucose control time in the blood glucose data is lower than a preset threshold value, performing parameter updating on the large language model. According to the invention, personalized monitoring and intervention effects on the diabetic patient can be improved.

A diabetes management system optimizes glucoregulatory hormone delivery using a connected glucoregulatory hormone delivery system and a computing device with a processor and non-transitory memory. The system receives glucose management data (glucose, insulin delivery, heart rate, or carbohydrate consumption data) from sensors. A digital twin metabolic model is selected and initialized based on the received data. The system simulates diabetes treatment interventions to predict glucose dynamics and determines an optimized glucoregulatory hormone parameter (e.g., insulin dose or increment that minimizes hyperglycemia and hypoglycemia risk). The determined glucoregulatory hormone parameter is transmitted to the connected glucoregulatory hormone delivery system, which may include an automated insulin delivery (AID) system or a connected insulin pen system, for implementation. By integrating real-time physiological data with predictive metabolic modeling, the system enhances glucoregulatory hormone therapy, providing personalized adjustments to improve glucose control.

Provided herein are methods for improving glycemic control in a human patient, methods for treating, preventing or reducing overweight or obesity and related co-conditions, and methods for treating or preventing type II diabetes mellitus by administering a polypeptide to the patient, the polypeptide comprises a fibronectin type III tenth (10Fn3) domain that binds to a myostatin. In some embodiments, the polypeptides are administered according to a specific clinical dosing regimen (e.g., at a specific dose and according to a specific time interval) (or for administration according to the regimen).

Exemplary embodiments relate to drug delivery devices, such as automated insulin delivery (AMD) devices. The described methods and apparatuses allow an AMD device to be initialized and / or operated with little or no user input. Exemplary logic initializes the AMD device to operate with known-safe drug delivery parameters that leverage the AMD device's ability to monitor blood glucose levels at short intervals and continuously deliver small amounts of insulin. The AMD then rapidly adapts the parameters and system constraints based on current and historical glucose measurements. Further embodiments provide for the detection of events that result in disturbances to glucose control, and to adaptation of alert frequency based on user behavior.

The invention discloses application of a fucoidin degradation product Fuc-S in a pharmaceutical composition for preventing, relieving or treating type 2 diabetes mellitus and liver injury, and relates to the technical field of biological medicines. The invention provides a new effect of fucoidin Fuc-S in treating diabetic liver injury, and particularly, the fucoidin Fuc-S can significantly improve blood glucose control (reducing fasting blood glucose and enhancing sugar tolerance) and blood lipid spectrum (reducing TG, TC and LDL-C and increasing HDL-C) of diabetic mice, alleviate liver fatty degeneration and reduce serum ALT / AST level, and shows a significant liver protection effect. Furthermore, the Fuc-S can be used for remodeling the intestinal flora structure through specific enrichment of beneficial bacteria such as Bacteroides acdifaciens and the like, so that the generation of short-chain fatty acid (SCFAs) with a liver protection effect is promoted. The flora and metabolic change jointly improve the oxidative stress state of the liver, inhibit pro-inflammatory response and reduce lipid accumulation. The invention provides a novel nutrition intervention strategy for prevention and treatment of T2DM and liver complications thereof.

The present disclosure relates to a method of preventing or treating a disease or disorder in a subject in need thereof, wherein administration of a composition of the present disclosure is effective to result in an increase of energy expenditure in the subject. The present disclosure provides a method of reducing fat mass and / or improving glycemic control in a subject in need thereof. The present disclosure provides a method of promoting weight loss and weight maintenance. The present disclosure provides a method of maintaining lean mass. Compositions for use in the methods include a compound of formula (I), (II), or (III), or pharmaceutically acceptable salts thereof, or in combination with a compound selected from the group consisting of an ACC2 inhibitor and an incretin mimetic.

Method, device and system for providing consistent and reliable glucose response information to physiological changes and / or activities is provided to improve glycemic control and health management.

The present invention provides a method of increasing glycemic control in a patient in need thereof by administering tizatide, or a pharmaceutically acceptable salt thereof. The present invention provides a method of improving body weight management in a patient in need thereof by administering tizatide, or a pharmaceutically acceptable salt thereof. Also provided is a method of treating a condition selected from the group consisting of atherosclerosis, chronic kidney disease, NAFLD and NASH. Also provided is a method of preventing or causing alleviation of diabetes mellitus, comprising administering tizatide or a pharmaceutically acceptable salt thereof. Also provided is a dosing regimen for increasing glycemic control, improving weight management, and / or treating dyslipidemia.

The invention provides a specific full-nutrient formula food applied to diet-restricted diabetes mellitus groups, and belongs to the technical field of formula foods for special medical purposes. According to the product, marine active substances and medicinal and edible traditional Chinese medicine extracts are innovatively compounded, and a multi-probiotic microencapsulation technology is combined, so that a specific full-nutrition formula with the functions of regulating blood sugar, improving insulin resistance and protecting target organ functions is formed. The formula comprises marine active ingredients such as marine collagen tripeptide, a sea cucumber saponin extract and fucoidan as well as medicinal and edible traditional Chinese medicine extracts such as mulberry leaves, rhizoma polygonati and radix puerariae, and oligopeptide, amino acid, multivitamins and mineral substances in a specific proportion are matched. Probiotics are protected by adopting a three-layer microencapsulation technology to pass through a gastric acid environment, active ingredients are reserved by utilizing a low-temperature enzymolysis and molecular directed extraction technology, and the nutritional status and blood sugar control of diabetic patients can be remarkably improved through clinical verification. The product conforms to the GB 29922-2013 special medical purpose formula food standard, can be used as a single nutrition source for diabetics, and meets the special nutrition requirements of the diabetics.

A medical device and method for determining a basal dose of insulin and a bolus dose of insulin to be administered for glycemic control is provided. The medical device includes an insulin pump, a control interface including a button configured to select one of a plurality of present bolus insulin doses based on input from a user (e.g., a patient), and a controller configured for executing instructions to determine a basal insulin delivery rate based, at least in part, on a total daily basal insulin dose and to determine the plurality of preset bolus insulin doses based, at least in part, on a total daily bolus insulin dose.

The invention discloses a low-GI biscuit with a blood sugar regulating function and a preparation method of the low-GI biscuit, and belongs to the technical field of food processing. The low-GI biscuits comprise water and oil wrappers and bakery shortening dough, and the water and oil wrappers comprise buckwheat flour, low-gluten flour, edible oil, yeast and baking soda; the bakery shortening dough comprises high amylose corn starch, corn starch, edible oil, ground cinnamon and salt. Through the synergistic effect of all the components, the activity of alpha-amylase and alpha-glucosidase is inhibited, carbohydrate digestion is delayed, and the GI value is reduced. The low-GI biscuit prepared by the preparation method disclosed by the invention has a crisp taste and an antibacterial effect, and a safe and effective food choice is provided for diabetics and crowds with blood glucose control.

The invention provides curcumin-nano-selenium modified Chinese chestnut starch with an irregular granular porous network structure, and belongs to the technical field of starch processing. The preparation method comprises the following steps: mixing a sodium selenite solution and a curcumin solution, and reacting under an alkaline condition to obtain a curcumin-nano-selenium solution; carrying out heat-moisture treatment on the starch suspension, and then freeze-drying to obtain heat-treated starch; preparing the heat-treated starch into a suspension 1, mixing the suspension 1 with the curcumin-nano-selenium solution, performing a constant-temperature oscillation reaction under a dark condition, and after the reaction is finished, cooling and drying to obtain the modified starch. According to the invention, a spherical aggregate of natural starch is reconstructed into an irregular granular porous network structure, so that the freeze-thaw stability, retrogradation stability, oxidation resistance and digestion resistance of the starch are remarkably improved. Moreover, based on a mouse experiment result, the modified starch has a good blood sugar control effect.

Various methods and apparatus for treating a condition associated with impaired glucose regulation in a subject comprising in one embodiment, applying a neural conduction block to a target nerve at a blocking site with the neural conduction block selected to at least partially block nerve pulses. In another embodiment, combinations of down-regulating and or up-regulating with are used to treat impaired glucose regulation. In other embodiments, up-regulation or down-regulation of various nerves, such as the vagus and its branches, are used to modify the secretion of insulin and glucagon from the pancreas, thereby controlling glucose levels. In yet further embodiments, combinations of down-regulating and or up-regulating are used to control sensitivity of the liver to plasma insulin and glucagon to treat impaired glucose regulation.

Provided are a method, system, and computer-readable medium for optimizing glycemic control of a diabetic subject having Type 1 diabetes through co-administration of sodium-glucose cotransporter inhibitors (SGLTi) and insulin. Such co-administration can be effected by, for example, regulating one or more administration reactions in view of analyses of continuous glucose monitoring (CGM) data that can be indicative of at least the potential for one or more glycemic events including hypoglycemia and hyperglycemia. The aforementioned regulation can occur according to a balancing of insulin infusion and provisioning of SGLTi so as to avoid the occurrence of either of such events while, at the same time, not promoting an instance of diabetic ketoacidosis (DKA).

Provided are methods for treating glucose-related metabolic disorders in a subject. In some aspects, the methods comprise enterally administering an effective amount of a beta-glucan oligosaccharide prior to and / or during the subject consuming a glucose source.

The invention discloses a personalized blood glucose management method and system for a diabetic patient, and relates to the technical field of personalized management methods, and the method comprises the steps: determining the blood glucose management logic of the diabetic patient according to a plurality of blood glucose control regions and the age of the diabetic patient; the blood glucose management logic is triggered based on the current blood glucose data and the blood glucose variation of the diabetic patient, and the corresponding blood glucose personalized management event is determined according to the blood glucose management level of the diabetic patient and the current event of the diabetic patient, so that the accuracy of the blood glucose personalized management event is ensured. Therefore, the mobile phone worn by the diabetic presents the corresponding blood glucose personalized management content, and records the execution progress of the blood glucose personalized management content; if the execution progress of the personalized blood glucose management content is lower than the preset execution progress threshold value, a blood glucose early warning event built in the mobile phone is triggered, and the diabetic patient is directly informed of an associated early warning contact person, so that the personalized blood glucose management effect of the diabetic patient is further realized.

To provide modified or polymer conjugated MetAP2 inhibitors.SOLUTION: The present invention relates to methods of preventing, inducing, causing or increasing weight loss, treating obesity and / or treating metabolic syndrome utilizing the modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of improving insulin sensitivity and glycemic control, reducing insulin levels and / or improving leptin sensitivity utilizing the modified or polymer conjugated MetAP2 inhibitors.SELECTED DRAWING: Figure 1

The present application relates to the technical field of mRNA vaccine, and specifically discloses a proinsulin mRNA vaccine for protecting the function and quantity of pancreatic beta cells. The vaccine is composed of a lipid nanoparticle (LNP) and an mRNA wrapped by the LNP; the mRNA is an mRNA sequence encoding proinsulin, and all uridines in the mRNA sequence are replaced by N1-methyl pseudouridine. The mRNA vaccine of the present application realizes the dual protection of the quantity and function of pancreatic beta cells, compared with the existing intervention means which only focus on blood glucose control or immune regulation, the present application delays the occurrence process of type 1 diabetes from the root, and provides a new technical scheme and drug selection for the prevention and early intervention of type 1 diabetes.

A diabetes management system optimizes glucoregulatory hormone delivery using a connected glucoregulatory hormone delivery system and a computing device with a processor and non-transitory memory. The system receives glucose management data (glucose, insulin delivery, heart rate, or carbohydrate consumption data) from sensors. A digital twin metabolic model is selected and initialized based on the received data. The system simulates diabetes treatment interventions to predict glucose dynamics and determines an optimized glucoregulatory hormone parameter (e.g., insulin dose or increment that minimizes hyperglycemia and hypoglycemia risk). The determined glucoregulatory hormone parameter is transmitted to the connected glucoregulatory hormone delivery system, which may include an automated insulin delivery (AID) system or a connected insulin pen system, for implementation. By integrating real-time physiological data with predictive metabolic modeling, the system enhances glucoregulatory hormone therapy, providing personalized adjustments to improve glucose control.

The invention relates to the technical field of medical informatics, and provides a diabetic diet optimization recommendation system based on deep learning. According to the system, structural feature construction is conducted on blood glucose, diet and life behavior data, blood glucose response structural decoupling, meal anchoring and cross-day stability features are introduced, and fine description of individual postprandial blood glucose dynamic response is achieved; in the blood glucose response prediction process, a local Dirichlet energy constrained deep learning model is introduced to improve the stability and generalization consistency of a prediction result; and a joint distribution density reasoning mechanism is combined to enhance the robust processing capability of missing follow-up visit data. On the basis, an individualized diet optimization recommendation result is generated by introducing a reinforcement learning method, collaborative optimization of blood glucose control, nutrition balance and patient compliance is achieved, and reliable intelligent decision support is provided for diabetes mellitus follow-up visit management.